Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Dronabinol-HIV
NCT06034314Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dronabinol in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Yale University. Primary endpoint: Change in Dronabinol-induced transcriptome profile in blood using single cell (sc)RNA-seq at 360 minutes. Started Sep 2023; status: active, not recruiting.
02
Drugs
dronabinol
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06034314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034314.